SLC6A3 and Parkinson disease: Patient preferences for DAT in advanced PD have received some attention in the recent years (Marshall et al. 2017; Aydemir et al. 2022), particularly for DBS (Shpiner et al. 2019; Das et al. 2021; Jost et al. 2022; Vinke et al. 2022; Alfonso et al. 2022; Montemayor et al. 2022), including preferences for its earlier use (Cabrera et al. 2020, b; Sperens et al. 2017; Alfonso et al. 2022; Montemayor et al. 2022).